AMRX (Amneal Pharmaceuticals) Insider Ownership: 2.90 % (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMRX Amneal Pharmaceuticals Inc AMRX
57 GF Score
Price $17.69
GF Value $8.17
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals Insider Ownership?

Amneal Pharmaceuticals AMRX +0.17% 57 Insider Ownership is 2.90 % as of Aug. 13, 2026. GuruFocus rates AMRX with a GF Score™ of 57/100 and a GF Value™ of $8.17 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Amneal Pharmaceuticals's insider ownership is 2.90%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Amneal Pharmaceuticals's Institutional Ownership is 50.46%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Amneal Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 70.41%.

Amneal Pharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals Insider Ownership Chart

Amneal Pharmaceuticals Historical Data

The historical data trend for Amneal Pharmaceuticals can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 2.50 2.20 2.20 2.20 2.18 2.18 2.18 2.90 2.90 2.90
AMRX
57GF Score
Amneal Pharmaceuticals Inc AMRX
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amneal Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 2.90 % mean?
Amneal Pharmaceuticals (AMRX) has a Insider Ownership of 2.90 % as of Aug. 13, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Amneal Pharmaceuticals and its competitors.
Is Amneal Pharmaceuticals' Insider Ownership too high?
Amneal Pharmaceuticals' current Insider Ownership is 2.90 %. Overall, Amneal Pharmaceuticals has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Insider Ownership compare to HIMS and KNSA?
Amneal Pharmaceuticals' Insider Ownership of 2.90 % can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Drug Manufacturers company?
A good Insider Ownership depends on the Drug Manufacturers industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current Insider Ownership is 2.90 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $8.17, compared to a current price of $17.69 — trading 116.5% above its estimated fair value. The current Insider Ownership is 2.90 %. Amneal Pharmaceuticals' overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current Insider Ownership is 2.90 % as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of $17.69 is trading 116.5% above its estimated GF Value™ of $8.17. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for AMRX:

  • Insider Ownership: 2.90 %
  • GF Value™: $8.17 vs. price of $17.69 (116.5% above fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Other Exchanges 2DT:Germany
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
57GF Score

Get the complete analysis for AMRX

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.69
Price
$8.17
GF Value